Mogamulizumab: First global approval

Drugs

Volumn 72, Issue 9, 2012, Pages 1293-1298

  Subramaniam, Joshuan M ^a   Whiteside, Glenn ^a   McKeage, Kate ^b   Croxtall, Jamie C ^b  

^a Adis R and D Insight   (New Zealand)

^b ADIS INTERNATIONAL LIMITED   (New Zealand)

Author keywords

Adult T cell leukaemia lymphoma; Asthma; Cutaneous T cell lymphoma; Haematological malignancies; Intravenous; Mogamulizumab; Peripheral T cell lymphoma

Indexed keywords

CYCLOPHOSPHAMIDE; DOXORUBICIN; MOGAMULIZUMAB; POTELIGEO; PREDNISOLONE; RANIMUSTINE; UNCLASSIFIED DRUG; VINCRISTINE;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANEMIA; AREA UNDER THE CURVE; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; ASTHMA; BACKACHE; CHILL; CUTANEOUS T CELL LYMPHOMA; CYTOKINE RELEASE SYNDROME; DIARRHEA; DOSE RESPONSE; DRUG APPROVAL; DRUG BLOOD LEVEL; DRUG DOSE ESCALATION; DRUG HALF LIFE; DRUG RESPONSE; FEBRILE NEUTROPENIA; FEVER; HEADACHE; HERPES ZOSTER; HUMAN; HYPOPHOSPHATEMIA; HYPOXEMIA; INFUSION RELATED REACTION; LEUKOPENIA; LYMPHOCYTOPENIA; MAXIMUM PLASMA CONCENTRATION; MYCOSIS FUNGOIDES; NAUSEA AND VOMITING; NEUTROPENIA; PRURITUS; RASH; SEZARY SYNDROME; SIDE EFFECT; STEVENS JOHNSON SYNDROME; T CELL LEUKEMIA; T CELL LYMPHOMA; THROMBOCYTOPENIA; TREATMENT RESPONSE;

ANTIBODIES, MONOCLONAL, HUMANIZED; CLINICAL TRIALS AS TOPIC; DRUG APPROVAL; HUMANS; RECEPTORS, CCR4;

EID: 84862126172     PISSN: 00126667     EISSN: 11791950     Source Type: Journal    
DOI: 10.2165/11631090-000000000-00000     Document Type: Article

References (17)

1. Ishida T, Ueda R. Antibody therapy for adult T-cell leukaemia-lymphoma. Int J Hematol 2011; 94: 443-52
2. Proietti FA, Carnieiro-Proietti ABF, Catalan-Soares BC, et al. Global epidemiology of HTLV-1 infection and associated diseases. Oncogene 2005; 24: 6058-68 (Pubitemid 43086123)
3. Kyowa Hakko Kirin Co Ltd. New Drug Application Approval for POTELIGEO (Mogamulizumab) Injection in Japan, a Therapeutic Antibody for Adult T-cell Leukemia-Lymphoma (ATL). www.kyowa-kirin.co.jp, 30 Mar 2012
4. Kyowa Hakko Kirin Co Ltd. Kyowa Hakko Kirin submitted New Drug Application in Japan for KW-0761,a Therapeutic Antibody for Adult T-cell Leukemia-Lymphoma (ATL). www.kyowa-kirin.co.jp, 26 Apr 2011
5. Kyowa Hakko Kirin Co Ltd. Kyowa Hakko Kirin Announces Results from Japan Phase 2 Clinical Trial of KW-0761 (Anti-CCR4 Humanized Monoclonal Antibody) in Patients with Recurrent or Relapsed Adult T-Cell Leukemia-Lymphoma (ATL). www.kyowa-kirrin.co.jp, 07 Dec 2010
6. Kyowa Hakko Kogyo Co Ltd, Kirin Pharma Company Limited, Kirin Holdings Company Limited. Strategic Alliance Between Kyowa Hakko Group and Kirin Group Maximizing Synergy Through an Alliance Centered Around the Pharmaceutical Business. www.kyowa.co.jp, 22 Oct 2007
7. Kyowa Hakko Kogyo Co Ltd, Amgen. Kyowa Hakko and Amgen Enter Licensing Agreement for Anti-CCR4 Humanized Monoclonal Antibody. www.kyowa.co.jp, 06 Mar 2008
8. Kyowa Hakko pipeline dated 31/1/12. http://www.kyowakirin. co.jp/english/rd/pipeline/pdf/pipeline-e-20120131.pdf
9. Ishii T, Ishida T, Utsunomiya A et al. Defucosylated humanized anti-CCR4 monoclonal antibody KW-0761 as a novel immunotherapeutic agent for adult T-cell leukaemia/lymphoma. Clin Cancer Res 2010; 16: 1520-31
10. Ishida T, Iida S, Akatsuka Y, et al. The CC chemokine receptor 4 as a novel specific molecular target for immunotherapy in adult T-cell leukemia/lymphoma. Clin Cancer Res 2004; 10: 7529-39 (Pubitemid 39557514)
11. Yano H, Ishida T, Inagaki A, et al. Defucosylated anti-CC chemokine receptor 4 monoclonal antibody combined with immunomodulatory cytokines: a novel immunotherapy for aggressive/refractory mycosis fungoides and Sezary syndrome. Clin Cancer Res 2007; 13: 6494-500 (Pubitemid 350075040)
12. Ito A, Ishida T, Utsunomiya A, et al. Defucosylated anti-CCR4 monoclonal antibody exerts potent ADCC against primary ATLL cells mediated by autologous human immune cells in NOD/Shi-scid, IL-2Rgnull mice in vivo. J Immunol 2009; 183: 4782-91
13. Ishida T, Joh T, Uike N, et al. Defucosylated anti-CCR4 monoclonclonal antibody (KW-0761) for relapsed adult T-cell leukaemia-lymphoma: a multicentre phase II study. J Clin Oncol 2012 March 10; 30 (8): 837-42
14. Yamamoto K, Utsunomiya A, Tobinai K, et al. Phase I study of KW-0761, a defucosylated humanized anti-CCR4 antibody, in relapsed patients with adult T-cell leukemialymphoma and peripheral T-cell lymphoma. J Clin Oncol 2010; 28 (9): 1591-8
15. Duvic M, Pinter-Brown L, Foss FM et al. Results of a phase 1/2 study for KW-0761, a monoclonal antibody directed against CC chemokine receptor type 4 (CCR4), in CTCL patients. Blood (ASH Annual Meeting Abstracts), Nov 2010; 116: 962
16. Kyowa Medex Co Ltd.Kyowa Medex Receives Approval for POTELIGEO TEST IHC and POTELIGEO TEST FCM, Companion Diagnostics of POTELIGEO Injection in Japan. www.kyowa-kirin.co.jp, 30 Mar 2012
17. Kyowa Medex Co Ltd.Kyowa Medex Submitted New Drug Application for In Vitro Diagnostic Reagent to Detect CCR4 Proteins in Japan. www.kyowamx.co.jp, 26 Apr 2011